BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23

• Press Releases

  ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

  October 23, 2026

   · 

  4 min read
• Press Releases

  Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea

  October 23, 2026

   · 

  3 min read
• Press Releases

  IBA signs major contract for a high-throughput Be Efficient sterilization solution in Germany

  October 23, 2026

   · 

  3 min read
• Press Releases

  Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

  October 23, 2026

   · 

  7 min read
• Press Releases

  Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

  October 23, 2026

   · 

  7 min read
• Press Releases

  Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

  October 23, 2026

   · 

  5 min read
• Press Releases

  Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

  October 23, 2026

   · 

  5 min read
• Press Releases

  AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data

  October 23, 2026

   · 

  4 min read
• Press Releases

  Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer

  October 23, 2026

   · 

  8 min read
• Press Releases

  ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

  October 23, 2026

   · 

  6 min read